Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDROMEDA: AZD9750 With or Without Other Anticancer Drugs in Metastatic Castration-Resistant Prostate Cancer
jRCT2031250648Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of AZD9750 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD9750, Determination of OBD, MTD, and RDE(s)/RP2D of AZD9750 and 3 more. Started Feb 2026; status: active, not recruiting.
02
Drugs
AZD9750
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250648.